Literature DB >> 16002971

Alpha1-antitrypsin and neutrophil elastase imbalance and lung cancer risk.

Ping Yang1, William R Bamlet, Zhifu Sun, Jon O Ebbert, Marie-Christine Aubry, Michael J Krowka, William R Taylor, Randolph S Marks, Claude Deschamps, Stephen J Swensen, Eric D Wieben, Julie M Cunningham, Lee Joseph Melton, Mariza de Andrade.   

Abstract

OBJECTIVE: Imbalance between alpha(1)-antitrypsin and neutrophil elastase is an underlying cause of lung tissue damage that may create a favorable host environment for carcinogenesis. We conducted a case-control study to investigate whether genetic variations indicative of alpha(1)-antitrypsin deficiency (A1ATD) or an excess of neutrophil elastase modify lung cancer risk
DESIGN: The case patients were 305 consecutively identified primary lung cancer patients, and the control subjects were 338 community residents. Protease inhibitor-1 (PI1), encoding alpha(1)-antitrypsin, was typed by an isoelectric focusing assay. Neutrophil elastase-2 (ELA2), encoding neutrophil elastase, was typed by two single-nucleotide polymorphism sites. Multivariable logistic regression models tested the independent and interactive effects of PI1, ELA2, tobacco smoke exposure, COPD, and family history of lung cancer
RESULTS: Sex and ethnicity were comparable between case patients and control subjects, but case patients were more likely to be smokers, and to have a history of COPD, environmental tobacco smoke exposure, and a positive family history of lung cancer. Haplotype analysis indicated an overall strong association between the two ELA2 markers and lung cancer risk. Our best-fitting model showed significant and independent effects of the PI1-deficient allele (odds ratio [OR], 2.0; 95% confidence interval [CI], 1.4 to 3.0) and the ELA2 T-G haplotype (OR, 4.1; 95% CI, 1.9 to 8.9) on lung cancer risk, and an increased risk (OR, 2.6; 95% CI, 2.4 to 2.8) for individuals carrying both a PI1-deficient allele and a G-G haplotype
CONCLUSIONS: Genotypes indicative of A1ATD and/or an excess of neutrophil elastase are significantly associated with lung cancer risk. Our findings may provide opportunities to better understand the mechanisms of lung cancer development and risk reduction.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16002971     DOI: 10.1378/chest.128.1.445

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  32 in total

1.  Genetic variations in multiple drug action pathways and survival in advanced stage non-small cell lung cancer treated with chemotherapy.

Authors:  Yafei Li; Zhifu Sun; Julie M Cunningham; Marie C Aubry; Jason A Wampfler; Gary A Croghan; Cassandra Johnson; Danli Wu; Jeremiah A Aakre; Julian Molina; Liewei Wang; V Shane Pankratz; Ping Yang
Journal:  Clin Cancer Res       Date:  2011-06-01       Impact factor: 12.531

2.  Neutrophils are required for 3-methylcholanthrene-initiated, butylated hydroxytoluene-promoted lung carcinogenesis.

Authors:  Haris G Vikis; Andrew E Gelman; Andrew Franklin; Lauren Stein; Amy Rymaszewski; Jihong Zhu; Pengyuan Liu; Jay W Tichelaar; Alexander S Krupnick; Ming You
Journal:  Mol Carcinog       Date:  2011-10-17       Impact factor: 4.784

3.  SERPINA1 and ELA2 polymorphisms are not associated with COPD or lung cancer.

Authors:  Lindsey Enewold; Leah E Mechanic; Elise D Bowman; Elizabeth A Platz; Anthony J Alberg
Journal:  Anticancer Res       Date:  2012-09       Impact factor: 2.480

4.  A Strong Neutrophil Elastase Proteolytic Fingerprint Marks the Carcinoma Tumor Proteome.

Authors:  Michał Kistowski; Janusz Dębski; Jakub Karczmarski; Agnieszka Paziewska; Jacek Olędzki; Michał Mikula; Jerzy Ostrowski; Michał Dadlez
Journal:  Mol Cell Proteomics       Date:  2016-12-07       Impact factor: 5.911

5.  Alpha-1-antitrypsin phenotypes and neutrophil elastase gene promoter polymorphisms in lung cancer.

Authors:  Aleksandra Topic; Mila Ljujic; Aleksandra Nikolic; Natasa Petrovic-Stanojevic; Vesna Dopudja-Pantic; Marija Mitic-Milikic; Dragica Radojkovic
Journal:  Pathol Oncol Res       Date:  2010-06-03       Impact factor: 3.201

6.  Origin and Functions of Tumor-Associated Myeloid Cells (TAMCs).

Authors:  Antonio Sica; Chiara Porta; Sara Morlacchi; Stefania Banfi; Laura Strauss; Monica Rimoldi; Maria Grazia Totaro; Elena Riboldi
Journal:  Cancer Microenviron       Date:  2011-09-24

7.  Chronic obstructive pulmonary disease: an update of treatment related to frequently associated comorbidities.

Authors:  Nicola J Sinden; Robert A Stockley
Journal:  Ther Adv Chronic Dis       Date:  2010-03       Impact factor: 5.091

Review 8.  Systems biology coupled with label-free high-throughput detection as a novel approach for diagnosis of chronic obstructive pulmonary disease.

Authors:  Joanna L Richens; Richard A Urbanowicz; Elizabeth A M Lunt; Rebecca Metcalf; Jonathan Corne; Lucy Fairclough; Paul O'Shea
Journal:  Respir Res       Date:  2009-04-22

9.  Lung cancer and chronic obstructive pulmonary disease: needs and opportunities for integrated research.

Authors:  Antonello Punturieri; Eva Szabo; Thomas L Croxton; Steven D Shapiro; Steven M Dubinett
Journal:  J Natl Cancer Inst       Date:  2009-04-07       Impact factor: 13.506

10.  Lung inflammation, injury, and proliferative response after repetitive particulate hexavalent chromium exposure.

Authors:  Laura M Beaver; Erik J Stemmy; Arnold M Schwartz; Jesse M Damsker; Stephanie L Constant; Susan M Ceryak; Steven R Patierno
Journal:  Environ Health Perspect       Date:  2009-08-19       Impact factor: 9.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.